SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series September class, title,number 09/10

20100249401 - Process for the preparation of sterically hindered nitroxyl ethers: The present invention relates to a novel process for the preparation of a sterically hindered nitroxyl ether from the corresponding sterically hindered nitroxyl radical by reacting it with a carbonyl compound and a hydroperoxide. The compounds prepared by this process are effective stabilizers for polymers against harmful effects of light,... Agent: Basf Corporation Patent Department

20100249402 - Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteporosis comprising the same: The present invention relates to novel benzamidine derivatives, a process for the preparation thereof and a pharmaceutical composition for preventing or treating osteoporosis comprising the same. The benzamidine derivatives of the present invention effectively inhibit osteoclast differentiation at an extremely low concentration, and thus can be advantageously used for the... Agent: Arent Fox LLP

20100249403 - Use of oxazine compounds for making chromogenic materials: Heterocyclic compounds incorporating a [1,3]oxazine ring may be used to make chromogenic materials. These molecules switch from a colorless state to a colored form upon addition of either acid or base. In both instances, the [1,3]oxazine ring opens in response to the pH change forming an indolium cation, after the... Agent: Nixon & Vanderhye, PC

20100249404 - Method for carrying out chemical reactions with the aid of an inductively heated heating medium: The invention relates to a method for carrying out a chemical reaction for producing a target compound by heating in a reactor a reaction medium containing at least one first reactant, such that a chemical bond inside the first reactant or between the first and a second reactant is formed... Agent: Henkel Corporation

20100249405 - Organic compounds: The present invention relates to novel IAP inhibitor compounds of formula I:... Agent: Novartis Institutes For Biomedical Research, Inc.

20100249406 - Phenyl-substituted 1,3.5-triazine compound, process for producing the same, and organic electroluminescent device containing the same as component: wherein Ar1 and Ar2 independently represent substituted or unsubstituted phenyl, naphthyl or biphenylyl group; R1, R2 and R3 independently represent hydrogen atom or methyl group; X1 and X2 independently represent substituted or unsubstituted phenylene, naphthylene or pyridylene group; p and q independently represent an integer of 0 to 2; and... Agent: Greenblum & Bernstein, P.L.C

20100249407 - Novel compound having affinity to amyloid: wherein R1 is a radioactive halogen substituent; m is an integer of 0 to 4; and n is an integer of 0 or 1, provided that at least one of A1, A2, A3 and A4 represents a carbon, and R3 binds to a carbon represented by A1, A2, A3 or... Agent: Fitch, Even, Tabin & Flannery

20100249408 - Use of novel compound having affinity for amyloid, and process for production of the same: e

20100249409 - Process for stereoselective synthesis of lamivudine: The present invention discloses a process for stereoselective synthesis of Lamivudine comprising the following steps: (a) performing a glycosylation-reaction between the compound of formula (I) and cytosine or protected cytosine, and separating the reaction product by recrystallization to obtain the intermediate of formula (II); and (b) deprotecting the intermediate of... Agent: Dorsey & Whitney LLP Intellectual Property Department

20100249410 - Process for preparing n-alkylated hydroxypyrimidinone compounds: e

20100249411 - Stereoselective alkylation of chiral 2-methly-4 protected piperazines: In an illustrative embodiment, the present invention describes the synthesis of the following compound and similar compounds, in high stereochemical purity by a novel stereoselective alkylation process:... Agent: Merck Patent Department (k-6-1, 1990)

20100249412 - Process for the manufacture of dihydropteridinones:

20100249413 - Stabilized pharmaceutical composition: [Means for Solution] Related are a stable pharmaceutical composition of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium or a pharmaceutically acceptable salt thereof, containing one kind or two or more kinds selected from the group consisting of carbazochrome sodium sulfonate and derivatives thereof, vitamin C's, butylhydroxylanisol, vitamin E's, Vitamin P's, gallic acid, propyl gallate, alpha-thioglycerine and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100240889 - Urea derivatives methods for their manufacture and uses thereof: The present invention provides compounds of formula (I): in which R1, R′1, R2, R′2, R3, Y and G have the meanings given in the description, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.... Agent: Amgen Inc.

20100240890 - Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same: The present invention relates to novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same. The novel benzamidine derivatives of the present invention are useful for the prevention and treatment of osteoporosis, bone fractures and allergic inflammatory diseases.... Agent: Arent Fox LLP

20100240891 - Drug containing benzophenone derivative or its salt: wherein the each substituent is as defined in the specification, or salts thereof have suppressive effect on RANKL production, suppressive effect on OPG reduction and inhibitory effects on differentiation/activation of osteoclasts, and are extremely useful for treating, for example therapy and/or prevention, of various diseases in which differentiation/activation of osteoclast... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100240892 - Electroluminescent device: Disclosed are electroluminescent devices that comprise organic layers that contain certain organic compounds containing one ore more pyrimidine moieties. The organic compounds containing one ore more pyrimidine moieties are suitable components of blue-emitting, durable, organo-electroluminescent layers. The electroluminescent devices may be employed for full color display panels in for example... Agent: Basf Corporation Patent Department

20100240893 - Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof: The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products... Agent: Townsend And Townsend And Crew, LLP

20100240894 - Method for producing amines from glycerin: The present invention relates to a process for preparing amines by reacting glycerol with hydrogen and an aminating agent from the group of ammonia and primary and secondary amines in the presence of a catalyst at a temperature of from 100° C. to 400° C. and a pressure of from... Agent: Connolly Bove Lodge & Hutz, LLP

20100234591 - Biaryl heterocyclic compounds and methods of making and using the same: The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at least one heterocylic moiety that are useful as such agents.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100234592 - Corrosion inhibitors having increased biodegradability and reduced toxicity: where R1 is C1- to C30-alkyl, C2- to C30-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, R2 is C1- to C30-alkyl, C2- to C30-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, or an optionally heteroatom containing organic radical having from 1 to 30 carbon atoms, and R3 and R4 are... Agent: Clariant Corporation Intellectual Property Department

20100234593 - imidazo[4,5-b]pyridine-7-carboxamides 704: The present invention relates to new compounds of formula (I) as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100234594 - Inhibitor of binding of s1p1: (wherein Y1 represents a nitrogen atom or a group represented by CRA, Y2 represents a nitrogen atom or a group represented by CRB, Y3 represents a nitrogen atom or a group represented by CRC, RA, RB and RC, which may be the same or different, each represent a hydrogen atom,... Agent: Sughrue Mion, PLLC

20100234595 - Nitrogen-containing heterocyclic compound: A nitrogen-containing heterocyclic compound is represented by Formula (I): wherein R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, or a substituted or unsubstituted alkoxy group having 1 to 20 carbon atoms; A represents a heterocyclic residue that contains at least one... Agent: Oliff & Berridge, PLC

20100234596 - Novel organic metal complex and process for preparing amine compound: n

20100234597 - Process for producing imidazo[1,2-b]pyridazine compound: wherein R1, R2 and R3 are the same meanings as defined above, with a phosphorus oxyhalide in the presence of an organic base which is in an amount of 0.5 mole or more relative to 1 mole of the 2,3-dihydropyridazine compound and 1 mole or less relative to 1 mole... Agent: Panitch Schwarze Belisario & Nadel LLP

20100234598 - Process for the preparation of imatinib and intermediates thereof: It is the object of the present invention a process for the preparation of 4-methyl-N3-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine and analogues thereof, intermediates useful for the synthesis of Imatinib, or 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide.... Agent: Dickstein Shapiro LLP

20100234599 - Method for preparing acid addition salts of polyacidic basic compounds:

20100228025 - Structured organic films having an added functionality: A structured organic film with an added functionality comprising a plurality of segments and a plurality of linkers arranged as a covalent organic framework, wherein the structured organic film may be a multi-segment thick structured organic film.... Agent: Oliff & Berridge, PLC.

20100228026 - Novel malonic acid sulfonamide derivative and pharmaceutical use thereof: The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effect(s) on various diseases due to its agonist action at AT2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the... Agent: Leydig Voit & Mayer, Ltd

20100228027 - Novel compounds of reverse turn mimetics and the use thereof (2): Conformationally constrained compounds that are novel and mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins and having bicyclic frame-work are disclosed, as well as their prodrugs. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and... Agent: Dickstein Shapiro LLP

20100228028 - Processes for the manufacture of rosuvastatin and intermediates: A process for the manufacture of a compound of formula (V), useful for making rosuvastatin, by a stereoselective aldol reaction is described. Novel intermediates and processes to make them are also described.... Agent: Morgan Lewis & Bockius LLP

20100228029 - Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application: Ligustrazine aromatic acid ether derivative of general formula I, its preparation method, pharmaceutical composition and application, wherein Ar is selected from aryl substituted aryl and substituted styryl, R is selected from hydrogen and alkyl with no more than 6 carbon atoms.... Agent: Zhen Zheng Lu

20100228030 - Process for the preparation of intermediates of tetracyclic compounds: The present invention relates to a process for the preparation of cis-intermediates of Formula II, (Formula II) wherein R1 represents hydrogen, (un)substituted alkyl, alkenyl, aryl, and X represents a leaving group, which are useful synthetic intermediates in the preparation of tetracyclic compounds having phosphodiesterase inhibitory activity.... Agent: Ranbaxy Inc.

20100222576 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses: P

20100222577 - Diimine metal complexes, methods of synthesis, and methods of using in oligomerization and polymerization: Novel α-diimine metal complexes, particularly iron complexes, having a phenyl sulfidyl or substituted phenyl sulfidyl metal complexing group are disclosed. The α-diimine metal complexes having a phenyl sulfidyl or substituted phenyl sulfidyl metal complexing group are produced by forming one of the α-diimine metal complex imine bonds in the presence... Agent: Chevron Phillips Chemical Company

20100222578 - Process for preparing acyl amide compounds: A process for preparing acyl amide compounds is described, in which a recrystallized o-nitrophenoxy carbonyl compound is hydrogenated with hydrogen gas in the presence of a nickel sponge metal catalyst with ring closure to form a benzoxazine, which is then reacted with an acyl halide to give the corresponding acyl... Agent: Lanxess Corporation

20100222579 - Process for the preparation of delmopinol and derivatives thereof: A process for the preparation of delmopinol (3-(4-propylheptyl)-4-morpholinethanol) or a derivative or a pharmaceutically acceptable salt, or a solvate thereof, including a hydrate, comprises reacting oxazolidin [2,3-c] morpholine and a Grignard reagent, and optionally converting the delmopinol (or derivative) free base into a pharmaceutically acceptable salt. The oxazolidin [2,3-c] morpholine... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100222580 - Process for the preparation of onium alkylsulfates having a low halide content: The invention relates to a process for the preparation of onium alkylsulfates by reaction of an onium halide with a symmetrically substituted dialkyl sulfate, in which the alkyl group can have 1 to 14 C atoms, with an asymmetrically substituted dialkyl sulfate, in which one alkyl group can have 4... Agent: Millen, White, Zelano & Branigan, P.C.

20100222581 - Novel isophthalates as beta-secretase inhibitors: or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure... Agent: Louis J. Wille Bristol-myers Squibb Company

20100222582 - Process for preparing melamine: Process for preparing melamine by converting urea in the presence of a solid catalyst in one reactor or in a plurality of reactors connected in series in the temperature range from 370° C. to 430° C., cooling and filtering the gas formed in the urea conversion, removing the melamine by... Agent: Connolly Bove Lodge & Hutz LLP

20100222583 - Diazaphosphacycle transition metal complexes: o

20100222584 - Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them: The present invention comprises methods of manufacturing a highly purified, pharmaceutical grade phthalazinedione for administration to a human or animal. The manufacturing methods identify and isolate starting materials, and prepare intermediate products, which are suitable for the commercial batch process production of highly purified and high-yielding intermediate products and final... Agent: Mccarter & English, LLP Boston

20100222585 - Preparation of dihydrothieno [3, 2-d] pyrimidines and intermediates used therein: The invention relates to improved methods of preparing dihydrothienopyrimidines of formula 1, and intermediates thereof, (I) wherein X is SO or SO2, preferably SO, and wherein RA, R1, R2, R3, R4 and R5 have the meanings given in the description. The methods according to this invention are more suitable for... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100222586 - Methods for producing sulfonic acid diamides: e

20100222587 - Compositions and methods for the intraocular transport of therapeutic agents: Membrane transporter-targeted therapeutic agents and methods of making and using the same.... Agent: Allergan, Inc.

20100222588 - Method for manufacture of 2-oxoimidazolidines: There is provided a method for manufacture of 2-oxoimidazolidines of Formula I comprising one or more of the steps of converting an amine to an acylation agent, condensation of the acylation agent with a bi-functional compound of structure L-C(R4)(R5)—C(R2)(R3)—NHR1, wherein L is a leaving group, and ring closure of the... Agent: Brouse Mcdowell Lpa